Key Metrics 
Check Before You Invest 
DeciZen 
10 Yrs X-Ray 
Profit & Loss 
Valuation 
Analyst Note 
Balance Sheet 
Cash Flow 
Financial Ratio 
Qtr. Results 
News 
About
Astec Lifesciences Ltd (ASTEC)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 533138 NSE: ASTEC Pesticides & Agrochemicals | Small Cap | Astec Lifesciences Share Price
₹659.10 -6.65 (-1.00%)
As on 24-Jul'26 16:59
Astec Lifesciences Ltd (ASTEC)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 533138 NSE: ASTEC Pesticides & Agrochemicals | Small Cap | Astec Lifesciences Share Price
₹659.10 -6.65 (-1.00%)
As on 24-Jul'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹1,483 Cr.
Current Price
₹659.1
52-Week Low / High
₹512 / 936
TTM EPS
₹-36.3
TTM Sales
₹448 Cr.
Book Value per Share
₹175.4
P/E Ratio
0.00
Industry PE
31.5
Price to Book (P/B)
3.80
Lower than its 5-year historical median
Price to Sales (P/S)
3.31
Lower than its 5-year historical median
EV/EBITDA
3523.87
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-25.88%
Underperforms industry median
Return on Capital Employed (ROCE)
-5.71%
Underperforms industry median
Return on Assets (ROA)
-8.84%
Operating Profit Margin
-1%
Net Profit Margin
-18.05%
Gross Profit Margin
-7.6%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
17.53%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
71.96%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹369 Cr.
Equity
₹22.3 Cr.
Face Value
₹10
All Time Low / High
₹14.35 / 2269.11
Check Before You Invest
Quality
Somewhat GoodValuation
UndervaluedCheck Valuation charts
Price Trend
Weak
Is Astec Lifesciences Ltd a good quality company?
Astec Lifesciences Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Astec Lifesciences Ltd performance compare with that of its Peers?
Revenue growth of Astec Lifesciences Ltd vs industry peers?
Astec Lifesciences Ltd revenue CAGR is -4.18%, compared to the industry median CAGR of 8.01%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Astec Lifesciences Ltd?
Promoters hold 71.96% of the Astec Lifesciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Astec Lifesciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 6.4% based on the current price.
DeciZen - make an informed investing decision on Astec Lifesciences
Decision Maker
Consolidated basis
1. Right Stock
10 Year X-ray Pro
Long Term Prospect
2. Right Price
3. Right Time ⓘ
#Likely Future 5 Year CAGR.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Astec Lifesciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 16.1% | 23.8% | 20.3% | 20.4% | 22.3% | 22.2% | 7.8% | -4.5% | -12.6% | -5.7% | - |
| Value Creation Index ⓘ | 0.2 | 0.7 | 0.5 | 0.5 | 0.6 | 0.6 | -0.5 | -1.3 | -1.9 | -1.4 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 458 | 381 | 448 | 448 |
| Sales YoY Gr. | - | 23.1% | 17.2% | 21.3% | 6.2% | 21.9% | -7.2% | -27.1% | -16.8% | 17.5% | - |
| Adj EPS ⓘ | 9.6 | 9.2 | 17.5 | 22.2 | 31.8 | 42.2 | 10.1 | -25.5 | -69.7 | -36.5 | -36.3 |
| YoY Gr. | - | -5.1% | 91.7% | 26.5% | 43.3% | 32.9% | -76.1% | -352% | NA | NA | - |
| BVPS (₹) ⓘ | 69.9 | 85.8 | 102.4 | 124.8 | 156.5 | 200.7 | 212.2 | 186.8 | 118.8 | 175.2 | 175.4 |
| Adj Net Profit ⓘ | 18.9 | 18 | 34.6 | 43.7 | 62.7 | 83.4 | 20 | -50.3 | -138 | -81.3 | -81 |
| Cash Flow from Ops. ⓘ | 19.2 | 64.7 | 15.3 | 168 | -8.2 | 23.6 | 74.7 | 10.2 | -8.4 | -80.7 | - |
| Debt/CF from Ops. ⓘ | 6.6 | 1.9 | 11.5 | 0.6 | -22.9 | 11.8 | 4.6 | 48.3 | -66 | -5.6 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 4.6% | -4.2% | -10.7% | 17.5% | ||||
| Adj EPS ⓘ | -215.9% | -202.8% | -253.4% | NA | ||||
| BVPSⓘ | 10.8% | 2.3% | -6.2% | 47.6% | ||||
| Share Price | 6.4% | -13.7% | -19.7% | -26.8% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 14.8 | 11.7 | 18.6 | 19.5 | 22.6 | 23.6 | 4.9 | -12.8 | -45.6 | -26 | -20.7 |
| Op. Profit Mgn % ⓘ | 21 | 18.7 | 17.8 | 16.3 | 20.1 | 22.8 | 12.2 | -1.3 | -17.4 | -1 | -1 |
| Net Profit Mgn % ⓘ | 6.4 | 4.9 | 8 | 8.4 | 11.3 | 12.3 | 3.2 | -11 | -36.1 | -18.1 | -18.1 |
| Debt to Equity ⓘ | 0.9 | 0.7 | 0.9 | 0.4 | 0.6 | 0.7 | 0.8 | 1.3 | 2.4 | 1.2 | 0.1 |
| Working Cap Days ⓘ | 248 | 233 | 223 | 217 | 229 | 244 | 316 | 379 | 368 | 332 | 174 |
| Cash Conv. Cycle ⓘ | 91 | 92 | 95 | 60 | 53 | 102 | 155 | 224 | 238 | 214 | -4 |
Profit And Loss
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 458 | 381 | 448 |
| Operating Expenses ⓘ + | 236 | 299 | 354 | 437 | 443 | 522 | 552 | 464 | 448 | 453 |
| Operating Profit ⓘ | 62 | 69 | 76 | 85 | 111 | 154 | 76 | -6 | -66 | -5 |
| Operating Profit Margin (%) | 20.9% | 18.7% | 17.7% | 16.3% | 20.1% | 22.8% | 12.1% | -1.3% | -17.4% | -1.0% |
| Other Income ⓘ + | 3 | 8 | 11 | 12 | 8 | 10 | 13 | 6 | 6 | 5 |
| Interest ⓘ | 12 | 11 | 12 | 13 | 5 | 9 | 21 | 25 | 37 | 35 |
| Depreciation ⓘ | 14 | 15 | 19 | 23 | 26 | 34 | 34 | 36 | 44 | 45 |
| Profit Before Tax ⓘ | 29 | 56 | 56 | 61 | 89 | 121 | 35 | -62 | -141 | -81 |
| Tax ⓘ | 10 | 21 | 20 | 14 | 24 | 31 | 9 | -15 | -6 | -0 |
| Profit After Tax | 19 | 35 | 36 | 48 | 65 | 90 | 26 | -47 | -135 | -81 |
| PAT Margin (%) | 6.4% | 9.5% | 8.3% | 9.1% | 11.7% | 13.3% | 4.1% | -10.2% | -35.3% | -18.1% |
| Adjusted EPS (₹) | 9.7 | 17.7 | 18.1 | 24.1 | 33.0 | 45.5 | 13.0 | -23.8 | -68.2 | -36.3 |
| Dividend Payout Ratio (%) | 15.30% | 8.40% | 8.20% | 6.20% | 4.50% | 3.30% | 11.50% | 0% | 0% | 0% |
Valuation of Astec Lifesciences - Consolidated
Analyst's Notes
No data found!
Balance Sheet
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 137 | 169 | 202 | 246 | 309 | 396 | 419 | 369 | 235 | 390 | |
| Debt + | 126 | 124 | 176 | 99 | 187 | 239 | 296 | 482 | 544 | 360 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 57 | 100 | 63 | 202 | 128 | 190 | 177 | 89 | 82 | 88 | |
| Others Liabilities ⓘ | 13 | 20 | 20 | 24 | 53 | 100 | 87 | 35 | 26 | 104 | |
| Total Liabilities ⓘ | 334 | 413 | 461 | 572 | 678 | 925 | 979 | 975 | 887 | 942 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 103 | 115 | 167 | 194 | 213 | 340 | 318 | 386 | 499 | 459 | |
| CWIP ⓘ | 8 | 42 | 19 | 24 | 116 | 23 | 127 | 165 | 21 | 20 | |
| Investments ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Inventories | 66 | 78 | 93 | 121 | 106 | 187 | 295 | 196 | 160 | 138 | |
| Trade Receivables | 111 | 123 | 122 | 161 | 187 | 274 | 155 | 169 | 147 | 248 | |
| Cash Equivalents | 4 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 12 | |
| Others Assets ⓘ | 43 | 53 | 59 | 70 | 54 | 100 | 82 | 57 | 57 | 65 | |
| Total Assets ⓘ | 334 | 413 | 461 | 572 | 678 | 925 | 979 | 975 | 887 | 942 | |
Cash Flow
(All Figures are in Crores.)| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 19 | 65 | 15 | 168 | -8 | 24 | 75 | 10 | -8 | -81 |
| Cash Flow From Investing Activity ⓘ + | -18 | -49 | -52 | -74 | -73 | -104 | -113 | -135 | -15 | -4 |
| Cash Flow From Financing Activity ⓘ + | -1 | -18 | 37 | -95 | 81 | 80 | 38 | 125 | 24 | 94 |
| Net Cash Flow ⓘ | 1 | -3 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 9 |
Financial Ratio
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 15.07 | 22.9 | 19.31 | 21.24 | 23.46 | 25.5 | 6.28 | -11.9 | -44.64 | -25.88 |
| ROCE (%) | 16.08 | 23.75 | 20.31 | 20.44 | 22.29 | 22.21 | 7.75 | -4.5 | -12.62 | -5.71 |
| Asset Turnover Ratio | 0.95 | 0.99 | 0.99 | 1.02 | 0.89 | 0.85 | 0.66 | 0.47 | 0.42 | 0.49 |
| PAT to CFO Conversion(x) | 1 | 1.86 | 0.42 | 3.5 | -0.12 | 0.27 | 2.88 | N/A | N/A | N/A |
| Working Capital Days | ||||||||||
| Receivable Days | 111.40 | 115.10 | 103.30 | 98.10 | 113.70 | 123.70 | 123.90 | 128.70 | 148.30 | 160.90 |
| Inventory Days | 79.70 | 70.90 | 72.30 | 74.30 | 74.20 | 78.70 | 139.30 | 195 | 166.70 | 121.30 |
| Payable Days | 126.90 | 121.90 | 106.60 | 143.20 | 176.40 | 150 | 166.90 | 152.30 | 105 | 103.50 |
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Astec Lifesciences Ltd FAQs
The current trading price of Astec Lifesciences on 24-Jul-2026 16:59 is ₹659.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-Jul-2026 the market cap of Astec Lifesciences stood at ₹1,483.5 Cr
The latest P/E ratio of Astec Lifesciences as of 23-Jul-2026 is 0.00.
The latest P/B ratio of Astec Lifesciences as of 23-Jul-2026 is 3.80.
The 52-week high of Astec Lifesciences is ₹936.0 and the 52-week low is ₹512.4.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Astec Lifesciences is ₹448 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Astec Lifesciences Ltd is a average quality company.
The key valuation ratios of Astec Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Astec Lifesciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Astec Lifesciences Ltd
Astec is proud of its rich experience of over two decades in the chemical industry. The company employs highly qualified and trained personnel to monitor and maintain its manufacturing activities as well as process development work. Astec prides itself in being responsive, reliable and quick to implement projects. A strong R&D focus has enabled the company to introduce a number of unique products. As the operations are highly integrated both vertically and horizontally, Astec has a very efficient, low cost structure in the market place.
Strong emphasis on quality, backed by a highly competent technical team, has enabled Astec to establish a successful track record in nurturing stable and long term relationships with highly reputed companies in USA, Japan and Europe. Above all, utmost respect for confidentiality, reliability, integrity and commitment in all its business relationships make Astec an ideal outsourcing partner. Astec Chemicals operates an ISO 9001:2000 certified Quality Assurance system.
The company has technologically sophisticated facilities for process development work and has demonstrated its ability to synthesize complex molecules rapidly. All its laboratories are equipped to carry out reactions from gm-scale to kilo-scale {up to 20 litres}.
Scale up to multikilo level is undertaken at its versatile 50-500 lts capacity pilot plant. Setting up a feasibility study through to laboratory development, pilot scale-up and full scale production are governed by the highest safety, quality and environmental standards.
Astec has multipurpose production facilities at two locations.
• Dombivli (50 km from Mumbai) • Mahad - two plants ( 180 kms from Mumbai)
They are multi-purpose plants based on 3,000-20,000 litres glasslined and stainless steel reactors. Typical reactors sizes are 10,000 lts.
• The pilot plant has glass and SS vessels of 50 litres to 500 litres capacity. • Reactions can be carried out from minus 20o C to 250o C. Distillation up to 300C • Vacuum down to 1mm Hg. • Distillation systems can handle high melting solids. • High efficiency fractionating columns up to 40 theoretical plates are available. • Facilities are designed to handle a number of corrosive and hazardous raw materials.
Products:
• Tebuconazole • Hexaconazole • Propiconazole • Metalaxyl • 1,2 Pentanediol • Dicap • 4-Fluoro phenacyl chloride.
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
